October 23, 2019
ICON’s buys Symphony Clinical Research
ICON has acquired Symphony Clinical Research, to boost its ability to offer customers hybrid trial solutions and site support services,…
Pharmaceuticals, Biotechnology and Life Sciences
Author: BusinessWire
October 23, 2019
Dr. Reddy’s confirms its voluntary recall of all ranitidine products in the U.S. market, as some samples contain a probable human carcinogen
Dr.Reddy’s has started a recall in USA of its ranitidine, to confirmed contamination with N-Nitrosodimethylamine (NDMA), classified as a probable…
October 23, 2019
Janssen to expand use of Tremfya in treatment of active psoriatic arthritis
Janssen has submitted a type II variation application to European Medicines agency, looking to get approved guselkumab, which could then…
October 23, 2019
Alexion ends third quarter 2019 with 23% increase in total revenues
Alexion finished the third quarter 2019 with total revenues of $1,263.1 million, which represents a 23% increase over 3the same…
October 23, 2019
FDA grants “Breakthrough Device Designation” to CorFlow Therapeutics to expedite clinical development and regulatory review of its CoFI system
The CoFI™ System is indicated for diagnostic assessment of the coronary microcirculation immediately following PCI (“stenting”), and to be a…
October 23, 2019
FDA approves Trikafta to treat cystic fibrosis in patients older than 12
Vertex Pharmaceuticals got approval from the USFDA for Trikafta, for treating cystic fibrosis in patients older than 12
October 23, 2019
Maze Therapeutics appoints City Hill founder to its Board of Directors
SOUTH SAN FRANCISCO–(BUSINESS WIRE)–Maze Therapeutics, a company focused on translating genetic insights into new medicines, today announced that Jonathan Lim,…
October 23, 2019
Abacus Health Products Successfully Obtains DTC Eligibility for its Subordinate Voting Shares
WOONSOCKET, R.I. & TORONTO–(BUSINESS WIRE)–$ABAHF #AbacusHealthProducts–Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announced that…
October 23, 2019
RAPT Therapeutics Announces Initiation of First-in-Human Phase 1 Study of RPT193
— Once-Daily, Orally Administered CCR4 Antagonist Blocks Recruitment of Th2 Inflammatory Immune Cells — — Potential to Treat Allergic Inflammatory…
October 23, 2019
Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual Scientific Meeting
CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #AMD—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies…